(NewsDirect)
Valeo Pharma chief executive Steve Saviuk joined Steve Darlingfrom Proactive to share news the company has been told by HealthCanada they have accepted for review Veru’s New Drug Submission(NDS-CV) for sabizabulin for COVID-19.
Saviuk told ProactiveSabizabulin is an antiviral and anti-inflammatory agent beingdeveloped for the treatment of hospitalized moderate to severeCOVID-19 adult patients at high risk for acute respiratory distresssyndrome and death. The company will now wait to hear back from HealthCanada.
ContactDetails
Proactive Investors
StephenGunnion
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.